Within the non-dilutive funding space one can find pockets of money in the billions of dollars directed at unmet medical needs related to CNS/PNS ailments. The scope of funding support covers much of the R&D cycle from proof of concept to late stage clinical. In the webinar in the series of summer educational webinars FreeMind […]
In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies. The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage […]
The U-Mechanism is a support mechanism used when there will be substantial Federal scientific or programmatic involvement by granting agency. Substantial involvement means that, after award, scientific or program staff will assist, guide, coordinate, or participate in project activities. We are seeing many programs utilizing this type of mechanism, with substantial awards being made to […]
Non-US applicants are eligible for the majority of the non-dilutive pockets of money including NIH, Department of Defense, BARDA etc. Currently, the National Institutes of Health (NIH) are actively funding over 1000 projects in the excess of $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations […]
Life Science Nation (LSN) and Johnson & Johnson Innovation, JLABS (JLABS) are inviting fundraising life science companies to attend the upcoming Redefining Early Stage Investments (RESI) Conference in Boston on September 16th. The first RESI Conference took place on September 16, 2013, and two years later, following highly successful events in San Francisco and Houston, LSN returns to Boston for the sixth […]
The National Institute of Allergies and Infectious Diseases (NIAID) awards close to $6,000,000,000 annually. Taking into account activities by DTRA, DARPA, US Army, BARDA etc. this is a funding force no one in the field can afford to ignore. Listen to FreeMind experts share insights into these tremendous sources of funding and get tips on […]
Every year NIH alone awards over $120,000,000 via R’-Mechanisms, among them the RO1 or R21. In order to maximize your funding potential all sources of funding must be considered including the less traditional sources. R21s aim to fund very early stage proof of concept type programs of up to 2 years at about $300,000, whereas […]
SBIR/STTR awards account for over $780,000,000 awarded per year by NIH alone to industry. These are excellent sources of funding aimed at promoting R&D activities of small businesses as well as collaborations with Academics. SBIR/STTRs differ from traditional NIH mechanisms in that they are highly product driven and ultimately are seeking commercialization of novel therapies, […]
This video was written, produced, and narrated by our own VP, Ayal Ronen. Ayal worked closely with Wander productions to make this excellent introductory video come to light.
Come say hello at our booth at the Bio International Convention taking place in Philadelphia – June 15 – 18, 2015. Ram May-Ron, Managing Partner, FreeMind Group and Guy-Har-Chen, FreeMind’s Chief Analyst will be taking meetings throughout the day in the booth. Come by for an Espresso, or drop your card to win a giant whiskey! (3.5L […]